Single molecule array measures of LRRK2 kinase activity in serum link Parkinson's disease severity to peripheral inflammation

Yuan Yuan,Huizhong Li,Kashyap Sreeram,Tuyana Malankhanova,Ravindra Boddu,Samuel Strader,Allison Chang,Nicole Bryant,Talene A. Yacoubian,David G. Standaert,Madalynn Erb,Darren J. Moore,Laurie H. Sanders,Michael W. Lutz,Dmitry Velmeshev,Andrew B. West

DOI: https://doi.org/10.1186/s13024-024-00738-4

2024-06-12

Molecular Neurodegeneration

Abstract:LRRK2-targeting therapeutics that inhibit LRRK2 kinase activity have advanced to clinical trials in idiopathic Parkinson's disease (iPD). LRRK2 phosphorylates Rab10 on endolysosomes in phagocytic cells to promote some types of immunological responses. The identification of factors that regulate LRRK2-mediated Rab10 phosphorylation in iPD, and whether phosphorylated-Rab10 levels change in different disease states, or with disease progression, may provide insights into the role of Rab10 phosphorylation in iPD and help guide therapeutic strategies targeting this pathway.

neurosciences